Castle biosciences stock.
Shares of Castle Biosciences, Inc. have returned +1.9% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it ...
Castle Biosciences Stock Down 0.1 %. NASDAQ:CSTL opened at $19.97 on Monday. Castle Biosciences, Inc. has a 52 week low of $9.26 and a 52 week high of $29.59. The company’s 50 day moving average ...Under the terms of the definitive agreement, AltheaDx will become a wholly owned subsidiary of Castle Biosciences. At closing, Castle will pay $65.0 million in initial consideration to AltheaDx ...Dec 1, 2023 · Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Castle Creek Biosciences: Cell and Gene Therapy Company : Castle Creek Biosciences, Inc. “ We are building a leading cell and gene therapy company for patients and families seeking relief from devastating genetic diseases. ”. Matthew Gantz, President and Chief Executive Officer. Courtesy of debra—The Dystrophic Epidermolysis Bullosa ...
Castle Biosciences (CSTL) In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences, with a price target of $38.00 . The company’s shares closed last ...DOI: 10.1200/JOP.2017.022152 Journal of Oncology Practice - published online before print March 28, 2017 . PMID: 28350513
Castle Biosciences Inc’s Stock Price as of Market Close. As of October 25, 2023, 4:00 PM, CST, Castle Biosciences Inc’s stock price was $12.66. Castle Biosciences Inc is down 4.24% from its previous closing price of $13.22. During the last market session, Castle Biosciences Inc’s stock traded between $12.78 and $13.25. …DOI: 10.1200/JOP.2017.022152 Journal of Oncology Practice - published online before print March 28, 2017 . PMID: 28350513
If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Castle Biosciences (CSTL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 2. Analyst Catherine Ramsey Schulte from Robert W. Baird remains ...Shares of Castle Biosciences ( CSTL 1.95%) were jumping 13.3% higher at 11:01 a.m. ET on Thursday. The nice gain came after the genetic testing company announced its second-quarter results ...Jun 15, 2023 · Shares of Castle Biosciences are trading down 1.98% over the last 24 hours, at $13.40 per share. A move to $30.00 would account for a 123.88% increase from the current share price. About Castle ... Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences Third Quarter 2023 Conference Call. As a ...
The estimated Net Worth of Mara G. Aspinall is at least $2.81 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $2,014,618 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.
Materials used to build castles include earth, wood and stone. Motte-and-bailey castles were made of earth and wood, but due to weaknesses in these castles, stone castles were created.
As soon as the Novitas decision reversal decision was announced, Castle stock began to climb, jumping from ~$13 per share, to nearly $20 per share, a >50% gain that leaves Castle more or less back ...Jun 5, 2023 · According to 7 analyst offering 12-month price targets in the last 3 months, Castle Biosciences has an average price target of $35.14 with a high of $41.00 and a low of $25.00. Castle Biosciences stock gains ~9% after co reports beat-and-raise Q2 SA News Tue, Aug. 09, 2022 1 Comment. Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $34.8M beats by $6.43MMar 20, 2023 · Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholders Tobin Juvenal CSTL stock SEC Form 4 insiders trading. Tobin has made over 5 trades of the Castle Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently Tobin exercised 6,173 units of CSTL stock worth $14,753 on 1 March 2023.6,173 units of CSTL stock worth $14,753 on 1 March 2023.Miles has made over 2 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,825 units of CSTL stock worth $76,653 on 2 June 2023.
Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholdersAt Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of …Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.The estimated Net Worth of Bernhard E. Spiess is at least $7.14 Million dollars as of 10 December 2021. Mr. Spiess owns over 1,500 units of Castle Biosciences stock worth over $346,275 and over the last 4 years he sold CSTL stock worth over $6,796,778. In addition, he makes $0 as Chief Business Officer at Castle Biosciences.Nov 30, 2023 · The latest price target for Castle Biosciences ( NASDAQ: CSTL) was reported by Keybanc on Friday, August 4, 2023. The analyst firm set a price target for 25.00 expecting CSTL to rise to within 12 ... Key Insights Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their...
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. But note: Castle Biosciences may not be the best stock to buy.So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).. Please note, the ...
CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 820 S. Friendswood Drive, Suite 201, Friendswood, Texas 77546 (Address of principal executive offices) (Zip Code) (866) 788-9007 Mr. Maetzold CSTL stock SEC Form 4 insiders trading. Derek has made over 105 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,500 units of CSTL stock worth $30,075 on 1 September 2023.. The largest trade he's ever made was exercising 65,627 units of Castle …Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 6.59% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $17.08 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to date ...Castle Biosciences is a pioneer in this field of spatial biology. Our biologically aware AI platform delivered Tissue Cypher® to the clinic, the world’s first precision medicine test to predict the risk of developing esophageal cancer in Barrett’s Esophagus patients – one of the world’s deadliest cancers. Castle Biosciences continues to pursue deployment …FRIENDSWOOD, Texas, November 08, 2023--Castle announces data demonstrating the impact of IDgenetix® on medication response/remission rates in patients with major …thefly.com — Castle Biosciences raises FY23 revenue view to at least $200M, consensus $187.1M News • Nov 1, 2023 GamesIndustry.biz — Remedy posts flat revenue for Q3 2023Castle Biosciences stock opened at $19.97 on Monday. The firm has a market capitalization of $537.39 million, a P/E ratio of -7.03 and a beta of 0.97. The company has a 50-day simple moving ...Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive …PURPOSE KRAS is the most mutated proto-oncogene that has been identified in cancer, and treatment of patients with KRAS mutations remains an arduous challenge. Recently, KRASG12C mutation has attracted special interest because it is now considered potentially druggable with recently developed covalent small-molecule KRASG12C inhibitors. …2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%)...
Discover historical prices for CSTL stock on Yahoo Finance. View daily, weekly or monthly format back to when Castle Biosciences, Inc. stock was issued.
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...
Nov 14, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago. Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.Nov 3, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new discovery data from an ongoing study exploring the potential for developing a complementary, minimally invasive test to evaluate small, suspicious lesions of uncertain malignant potential in patients’ eyes. Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript. Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences Third Quarter 2023 Conference Call. As a reminder, today’s call is being recorded.Stocks CSTL Overview Castle Biosciences Inc. U.S.: Nasdaq About Castle Biosciences Inc. Average price target from ratings: $ Full Ratings 52.55K (21.02% of Avg) 65 Day …Nov 24, 2023 · Castle Biosciences Inc CSTL Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating... Discover historical prices for CSTL stock on Yahoo Finance. View daily, weekly or monthly format back to when Castle Biosciences, Inc. stock was issued. Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 22.54% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $19.70 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ...
Jean Carruthers Faculty Owner/Co-Owner Founder/Co-Founder: Carruthers Instruments; Consulting Fee: Alastin Skincare, Allergan Aesthetics, Appiell, Avari, Evolus ...Jun 5, 2023 · Castle Biosciences Inc (CSTL) stock is down -47.58% while the S&P 500 has gained 0.08% as of 10:52 AM on Monday, Jun 5. CSTL is lower by -$10.81 from the previous closing price of $22.73 on volume of 2,678,434 shares. Over the past year the S&P 500 is up 3.99% while CSTL is lower by -44.69%. CSTL lost -$2.71 per share the over the last 12 months. The shares are expected to begin trading on The Nasdaq Global Market on July 25, 2019 under the symbol “CSTL.” All of the common stock in the offering is being ...Instagram:https://instagram. can you doordash weedrare quarter dollar valuequarter dollar coin 1776 to 1976 valuetop dental insurance providers Castle Biosciences, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead ... short qqqcan you transfer a brokerage account to another company CSTL Castle Biosciences, Inc. Stock Price & Overview 2.63K followers $19.99 0.13 ( +0.65%) 4:00 PM 11/30/23 NASDAQ | $USD | Post-Market: $19.99 4:17 …Castle Biosciences Stock Up 9.0 %. CSTL stock opened at $14.23 on Tuesday. The company has a market cap of $381.51 million, a PE ratio of -4.25 and a beta of 0.85. The business has a 50-day simple ... best funds for 401k Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 9.67% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $19.36 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to …Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Nov 17, 2023 · 4 Wall Street research analysts have issued 1-year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price.